Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients.


Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 18 08 2020
revised: 09 12 2020
accepted: 10 12 2020
pubmed: 14 1 2021
medline: 21 8 2021
entrez: 13 1 2021
Statut: ppublish

Résumé

New therapeutic drugs have been developed for non-small cell lung cancer (NSCLC), and the prognosis of advanced NSCLC patients has improved. However, resistance to these drugs is a concern, and re-biopsy is necessary to determine the mechanism of drug resistance. There are many reports about the protocols for re-biopsy, including techniques such as bronchoscopy and computed tomography-guided needle biopsy (CTNB); however, there is no consensus on which method is optimal. Therefore, we retrospectively reviewed the bronchoscopy and CTNB re-biopsies conducted at our hospital. We retrospectively analyzed 79 cases of re-biopsies with bronchoscopy or CTNB in patients with NSCLC from January 2014 to December 2016 at our institute. Forty-nine cases of bronchoscopy and 30 cases of CTNB were taken for re-biopsy. The diagnostic rates of bronchoscopy and CTNB were 83.7% and 100%, respectively (p = 0.023). The complication rates of bronchoscopy and CTNB were 18.4% and 36.7%, respectively (p = 0.11), with a statistically significant difference in the incidence of pneumothorax (0% vs. 23.3%, respectively; p < 0.01). Pneumothorax required drainage in 6.7% of all CTNB cases. There were no fatalities in either group. CTNB showed a higher diagnostic rate; however, it was associated with a higher rate of complications such as pneumothorax. Hence, the optimal modality must be determined individually for each patient.

Sections du résumé

BACKGROUND BACKGROUND
New therapeutic drugs have been developed for non-small cell lung cancer (NSCLC), and the prognosis of advanced NSCLC patients has improved. However, resistance to these drugs is a concern, and re-biopsy is necessary to determine the mechanism of drug resistance. There are many reports about the protocols for re-biopsy, including techniques such as bronchoscopy and computed tomography-guided needle biopsy (CTNB); however, there is no consensus on which method is optimal. Therefore, we retrospectively reviewed the bronchoscopy and CTNB re-biopsies conducted at our hospital.
METHODS METHODS
We retrospectively analyzed 79 cases of re-biopsies with bronchoscopy or CTNB in patients with NSCLC from January 2014 to December 2016 at our institute.
RESULTS RESULTS
Forty-nine cases of bronchoscopy and 30 cases of CTNB were taken for re-biopsy. The diagnostic rates of bronchoscopy and CTNB were 83.7% and 100%, respectively (p = 0.023). The complication rates of bronchoscopy and CTNB were 18.4% and 36.7%, respectively (p = 0.11), with a statistically significant difference in the incidence of pneumothorax (0% vs. 23.3%, respectively; p < 0.01). Pneumothorax required drainage in 6.7% of all CTNB cases. There were no fatalities in either group.
CONCLUSIONS CONCLUSIONS
CTNB showed a higher diagnostic rate; however, it was associated with a higher rate of complications such as pneumothorax. Hence, the optimal modality must be determined individually for each patient.

Identifiants

pubmed: 33436353
pii: S2212-5345(20)30186-6
doi: 10.1016/j.resinv.2020.12.001
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-246

Informations de copyright

Copyright © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest.

Auteurs

Hirohisa Kano (H)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: kotobukikaho.hiro@gmail.com.

Toshio Kubo (T)

Center for Clinical Oncology, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: t-kubo@cc.okayama-u.ac.jp.

Kiichiro Ninomiya (K)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: kiichiro.nino@gmail.com.

Eiki Ichihara (E)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: ichiha-e@md.okayama-u.ac.jp.

Kadoaki Ohashi (K)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: kohashi@cc.okayama-u.ac.jp.

Kammei Rai (K)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan; Hospital-based Cancer Registry Division, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: rai@okayama-u.ac.jp.

Katsuyuki Hotta (K)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan; Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: khotta@md.okayama-u.ac.jp.

Masahiro Tabata (M)

Center for Clinical Oncology, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: tabata@md.okayama-u.ac.jp.

Takao Hiraki (T)

Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: hirakitakao8@gmail.com.

Susumu Kanazawa (S)

Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: susumu@cc.okayama-u.ac.jp.

Yoshinobu Maeda (Y)

Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: yosmaeda@md.okayama-u.ac.jp.

Katsuyuki Kiura (K)

Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1, Kita-ku, Shikata-cho, Okayama City, Okayama, Japan. Electronic address: kkiura@md.okayama-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH